Clinical significance of extended high-risk human papillomavirus genotyping and viral load in cervical cancer and precancerous lesions

[1]  Chengquan Zhao,et al.  Risk stratification for cervical neoplasia using extended high‐risk HPV genotyping in women with ASC‐US cytology: A large retrospective study from China , 2021, Cancer cytopathology.

[2]  G. Ingravallo,et al.  HPV-Negative Cervical Cancer: A Narrative Review , 2021, Diagnostics.

[3]  Jiancui Chen,et al.  Use of extended HR-HPV Genotyping in improving the Triage Strategy of 2019 ASCCP recommendations in Women with positive HR-HPV diagnosis and Simultaneous LSIL Cytology Results , 2021, Journal of Cancer.

[4]  J. Su,et al.  Prevalence and genotype distribution of high‐risk HPV infection among women in Beijing, China , 2021, Journal of medical virology.

[5]  H. Zou,et al.  Effect of introducing human papillomavirus genotyping into real-world screening on cervical cancer screening in China: a retrospective population-based cohort study , 2021, Therapeutic advances in medical oncology.

[6]  M. Schiffman,et al.  2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors , 2020, Journal of lower genital tract disease.

[7]  Wenyu Lin,et al.  Evaluation of PCR-Reverse Dot Blot Human Papillomavirus Genotyping Test in Predicting Residual/Recurrent CIN 2+ in Posttreatment Patients in China , 2020, Cancer management and research.

[8]  M. Schiffman,et al.  Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines , 2020, Journal of lower genital tract disease.

[9]  M. Schiffman,et al.  2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation , 2020, Journal of lower genital tract disease.

[10]  Wenyu Lin,et al.  HR-HPV viral load quality detection provide more accurate prediction for residual lesions after treatment: a prospective cohort study in patients with high-grade squamous lesions or worse , 2020, Medical Oncology.

[11]  Jacques Ferlay,et al.  Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis , 2019, The Lancet. Global health.

[12]  J. Cuzick,et al.  Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[13]  Anne M Johnson,et al.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis , 2019, The Lancet.

[14]  Charles K. Cooper,et al.  Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology. , 2019, Gynecologic oncology.

[15]  Shaokai Zhang,et al.  Performance of Different Combination Models of High-Risk HPV Genotyping in Triaging Chinese Women With Atypical Squamous Cells of Undetermined Significance , 2019, Front. Oncol..

[16]  Charles K. Cooper,et al.  Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology. , 2019, Gynecologic oncology.

[17]  I. Karaca,et al.  Does the ‘equal management of equal risks’ model cause overtreatment in patients with positive cervical cytology results for ASCUS/non‐HPV16/18 oncogenic types? , 2018, Diagnostic cytopathology.

[18]  P. Sun,et al.  Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case– control study , 2018, Cancer management and research.

[19]  Qibin Wu,et al.  Cervical cancer screening using the Cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China , 2018, Cancer management and research.

[20]  T. Bjørge,et al.  Human papillomavirus type specific risk of progression and remission during long‐term follow‐up of equivocal and low‐grade HPV‐positive cervical smears , 2018, International journal of cancer.

[21]  Melina B. Flanagan.  Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening in the United States: Is It Time? , 2018, Archives of pathology & laboratory medicine.

[22]  M. Schiffman,et al.  Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening , 2018, Journal of the National Cancer Institute.

[23]  P. Parás-Bravo,et al.  Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions , 2018, BMC Cancer.

[24]  M. Henry,et al.  High-risk HPV genotype distribution in HPV co-test specimens: study of a predominantly Midwestern population. , 2017, Journal of the American Society of Cytopathology.

[25]  A. Lin,et al.  Prevalence of human papillomavirus genotypes and relative risk of cervical cancer in China: a systematic review and meta-analysis , 2015, Oncotarget.

[26]  Y. Qiao,et al.  Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study. , 2018, Gynecologic oncology.

[27]  N. Kiviat,et al.  Type‐dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18 , 2017, International journal of cancer.

[28]  P. Sun,et al.  Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study , 2017, Journal of gynecologic oncology.

[29]  Yu Qin,et al.  Association between human papillomavirus (HPV) 16, HPV18, and other HR‐HPV viral load and the histological classification of cervical lesions: Results from a large‐scale cross‐sectional study , 2017, Journal of medical virology.

[30]  E. Pirog,et al.  The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation‐wide multi‐center retrospective study across China , 2016, International journal of cancer.

[31]  Yang Zhang,et al.  Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China , 2016, Oncotarget.

[32]  S. Hur,et al.  Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification? , 2016, Journal of gynecologic oncology.

[33]  P. Suprasert,et al.  Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand , 2016, PloS one.

[34]  J. Cuzick,et al.  Need for expanded HPV genotyping for cervical screening☆ , 2016, Papillomavirus research.

[35]  S. Weyers,et al.  Evaluation of the clinical significance of human papillomavirus (HPV) 53. , 2015, European journal of obstetrics, gynecology, and reproductive biology.

[36]  E. Schuuring,et al.  Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China , 2015, BMC Infectious Diseases.

[37]  A. Kamat,et al.  Non‐16/18 high‐risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL , 2015, Cancer cytopathology.

[38]  T. Iftner,et al.  Long‐term risk of cervical intraepithelial neoplasia grade 3 or worse according to high‐risk human papillomavirus genotype and semi‐quantitative viral load among 33,288 women with normal cervical cytology , 2015, International journal of cancer.

[39]  J. T. Cox,et al.  Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. , 2015, Gynecologic oncology.

[40]  M. Noguchi,et al.  HPV genotyping for triage of women with abnormal cervical cancer screening results: a multicenter prospective study , 2015, International Journal of Clinical Oncology.

[41]  E. J. Mayeaux,et al.  Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. , 2015, Gynecologic oncology.

[42]  J. Ordi,et al.  HPV‐negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis , 2015, BJOG : an international journal of obstetrics and gynaecology.

[43]  M. Schiffman,et al.  A Study of Genotyping for Management of Human Papillomavirus-Positive, Cytology-Negative Cervical Screening Results , 2014, Journal of Clinical Microbiology.

[44]  Jack Cuzick,et al.  The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States , 2014, International journal of cancer.

[45]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[46]  G. Ripabelli,et al.  Type-specific persistence and associated risk factors of human papillomavirus infections in women living in central Italy. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[47]  D. Martins,et al.  Detection of Human Papillomavirus in biopsies of patients with cervical cancer, and its association with prognosis , 2013, Archives of Gynecology and Obstetrics.

[48]  James Mitchell Crow,et al.  HPV: The global burden , 2012, Nature.

[49]  N. Muñoz,et al.  Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention. , 2012, Gynecologic oncology.

[50]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[51]  Mark Schiffman,et al.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. , 2011, The Lancet. Oncology.

[52]  Y. Hirai,et al.  Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: A prospective cohort study , 2011, International journal of cancer.

[53]  H. Cho,et al.  HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB-IIA cervical cancer undergoing radical hysterectomy. , 2011, Gynecologic oncology.

[54]  S. Franceschi,et al.  Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication , 2011, International journal of cancer.

[55]  E. Díaz,et al.  Prevalence and Distribution of High-Risk Genotypes of HPV in Women with Severe Cervical Lesions in Madrid, Spain: Importance of Detecting Genotype 16 and Other High-Risk Genotypes , 2010, Advances in preventive medicine.

[56]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[57]  T. Iftner,et al.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.

[58]  J. Palmgren,et al.  Prospective Study of Human Papillomavirus (HPV) Types, HPV Persistence, and Risk of Squamous Cell Carcinoma of the Cervix , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[59]  J. Berkhof,et al.  High‐risk human papillomavirus DNA load in a population‐based cervical screening cohort in relation to the detection of high‐grade cervical intraepithelial neoplasia and cervical cancer , 2009, International journal of cancer.

[60]  S. Wacholder,et al.  Human Papillomavirus Cofactors by Disease Progression and Human Papillomavirus Types in the Study to Understand Cervical Cancer Early Endpoints and Determinants , 2009, Cancer Epidemiology Biomarkers & Prevention.

[61]  J. Dillner,et al.  HPV type-specific risks of high-grade CIN during 4 years of follow-up: A population-based prospective study , 2007, British Journal of Cancer.

[62]  L. Villa,et al.  CHAPTER 7 Methods for detection of HPV infection and its clinical utility , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.